China's patent reform waiting game

For the second consecutive meeting, the Standing Committee of China's National People’s Congress (NPC) adjourned April 23 without considering a revised draft of patent reforms that would extend protections for innovative drugs. While at least minor changes are expected before the country’s first IP overhaul in over a decade becomes law, the addition of patent linkage --

Read the full 574 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE